SSY Group Limited Reports Q1 2026 Unaudited Operating Results: Turnover Up, Gross Profit Margin Down
SSY Group Limited Reports Unaudited Q1 2026 Results: Turnover Up 8%, Gross Profit Margin Declines
SSY Group Limited (Stock Code: 2005) has released its unaudited operating results for the first quarter ended 31 March 2026. The announcement, made on a voluntary basis, provides investors with key insights into the company’s recent financial performance and operational trends.
Key Financial Highlights
- Turnover: The Group’s unaudited turnover for Q1 2026 reached approximately HK\$1,227 million, representing an 8.0% increase compared to HK\$1,136 million in Q1 2025.
- Gross Profit: Despite the growth in turnover, the unaudited gross profit declined by 1.3% to approximately HK\$502 million (Q1 2025: HK\$509 million).
- Gross Profit Margin: The gross profit margin dropped to 41.0%, a decrease of 3.8 percentage points from the previous year’s corresponding period. This signals rising costs or pricing pressure.
- Profit Attributable to Shareholders: The unaudited net profit attributable to shareholders increased modestly by 1.6% to HK\$171.2 million (Q1 2025: HK\$168.5 million).
Segment Performance Breakdown
SSY Group’s turnover is derived from a diversified portfolio of intravenous infusion (“IV”) solution products and non-IV solution products. The Q1 performance by product segment is as follows:
| Product Segment |
Q1 2026 Turnover (HK\$ million) |
YoY Change (%) |
% of Total Turnover |
| Non-PVC Soft Bag IV Solution |
325 |
+2.7% |
26.5% |
| Upright Soft Bag IV Solution |
186 |
+20.7% |
15.2% |
| PP Plastic Bottle IV Solution |
138 |
-2.4% |
11.2% |
| Glass Bottle IV Solution |
47 |
+18.8% |
3.9% |
| Ampoule Injection |
78 |
+0.2% |
6.3% |
| Bulk Pharmaceuticals |
316 |
+61.2% |
25.8% |
| Oral Preparations |
73 |
-51.8% |
6.0% |
| Medical Materials |
56 |
+10.1% |
4.5% |
| Other Products and Services |
8 |
-7.5% |
0.6% |
Key Observations & Price-Sensitive Information
- Strong Turnover and Bulk Pharmaceutical Growth: The 8% growth in turnover is driven notably by a surge of 61.2% in bulk pharmaceuticals, now contributing 25.8% of total turnover. Upright soft bag IV solutions (+20.7%) and glass bottle IV solutions (+18.8%) also delivered strong growth.
- Margin Pressure: Despite revenue growth, the decline in gross profit margin by 3.8 percentage points (to 41.0%) is significant. This could be from increased costs, competitive pricing, or changes in product mix, which may impact overall profitability if the trend continues.
- Weakness in Oral Preparations: The oral preparations segment saw a sharp 51.8% decline, which may indicate challenges in that product line or market segment.
- Stable Profitability: The company managed a modest increase in net profit attributable to shareholders (+1.6%), indicating that despite margin pressures, bottom-line growth was preserved, albeit at a slower rate than revenue growth.
- Unaudited Figures: Investors should note these results are unaudited and based on management accounts. Final audited numbers may differ, and no assurance is given regarding their accuracy at this stage.
- Potential Impact on Share Price: The results indicate robust top-line growth but highlight margin compression and operational challenges in some segments. These mixed signals may result in increased volatility and investor scrutiny. Positive drivers include strong growth in several segments and stable profits, but the margin decline is a notable risk factor for valuation.
Corporate Governance
The announcement was authorized by the Board, which comprises a mix of executive, non-executive, and independent non-executive directors, ensuring a degree of oversight and governance.
Investor Guidance
Shareholders and potential investors are advised to exercise caution when trading the Company’s shares, as unaudited interim results may be subject to change and could impact market perceptions and valuations depending on subsequent audited disclosures.
Disclaimer: The above article is based on unaudited management accounts as disclosed by SSY Group Limited for the period ended 31 March 2026. Actual audited results may differ due to various uncertainties. This article does not constitute investment advice. Investors are urged to exercise caution and consult their professional advisers before making any investment decisions.
View SSY GROUP Historical chart here
